The PEPR Biotherapies program has launched its first call for projects to support innovative initiatives in the field of biotherapies. After the evaluation process, six ambitious projects promising major advancements in research and healthcare have been selected. These projects will benefit from a total funding of 13.2 million euros.
Overview of Selected Projects
- Project COBRAS (€1.6M): Development of 3D bio-printed corneas for advanced surgical repair to improve the treatment of severe corneal lesions.
- Project HIBAL (€2.5M): Design of a bio-artificial liver combining stem cells with an external support device to effectively treat acute liver failure.
- Project MUSCLE (€1.8M): Development of a new generation of lipid nanoparticles specifically targeting muscle cells to deliver nucleic acid-based treatments for neuromuscular diseases.
- Project OptiCELL (€2.3M): Production of retinal tissues from stem cells integrating optogenetics and tissue engineering, enabling the transplantation of functional retinal cells for innovative ophthalmologic treatments.
- Project PARADIGM (€2.5M): Establishment of a phage biobank—viruses capable of eliminating pathogenic bacteria—coupled with novel sensitivity tests to quickly address antibiotic-resistant infections.
- Project REPLIBIO (€2.5M): Development of non-viral self-replicating vectors as a more efficient and economical alternative to current vectors, thereby facilitating broader access to gene therapies.
These projects exemplify the ambition of the PEPR Biotherapies program: supporting French scientific excellence in biotherapies and accelerating the emergence of major therapeutic innovations for patient benefit.
